Neutrophil gelatinase-associated lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids

Hypertension

Volumn 66, Issue 1, 2015, Pages 158-166

  Tarjus, Antoine ^a   Martínez Martínez, Ernesto ^b   Amador, Cristian ^a   Latouche, Céline ^a   El Moghrabi, Soumaya ^a   Berger, Thorsten ^c   Mak, Tak W ^c   Fay, Renaud ^d,e,f   Farman, Nicolette ^a   Rossignol, Patrick ^d,e,f   Zannad, Faiez ^d   López Andrés, Natalia ^b,d,e,f   Jaisser, Frédéric ^a,d,e,f  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b Atención Primaria Y Promoción de La Salud   (Spain)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

^e UNIVERSITÉ DE LORRAINE   (France)

^f INI CRCT   (France)

Author keywords

aldosterone; collagen type I; fibroblast; lipocalin 2; mineralocorticoid receptor

Indexed keywords

ALDOSTERONE; CARDIOTROPHIN 1; COLLAGEN TYPE 1; GALECTIN 3; GELATINASE B; MINERALOCORTICOID; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PEPTIDE; PROCOLLAGEN TYPE I N TERMINAL PEPTIDE; UNCLASSIFIED DRUG; ACUTE PHASE PROTEIN; CYTOKINE; LCN2 PROTEIN, HUMAN; LCN2 PROTEIN, MOUSE; LIPOCALIN; ONCOPROTEIN; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE; RECOMBINANT PROTEIN;

ABDOMINAL OBESITY; ADULT; ALDOSTERONE BLOOD LEVEL; ANIMAL CELL; AORTA; ARTICLE; COHORT ANALYSIS; COLLAGEN FIBER; CONTROLLED STUDY; CORONARY BLOOD VESSEL; EX VIVO STUDY; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; FIBROSIS; GENE INACTIVATION; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; VASCULAR FIBROSIS; ADVERSE EFFECTS; ANIMAL; BIOSYNTHESIS; BLOOD; CELL CULTURE; CHEMICALLY INDUCED; CYTOLOGY; DEFICIENCY; DRUG EFFECTS; GENETICS; HEART MUSCLE; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; HYPERTROPHY; KIDNEY; METABOLISM; NEPHRECTOMY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SMOOTH MUSCLE FIBER;

ACUTE-PHASE PROTEINS; ALDOSTERONE; ANIMALS; AORTA; CARDIOMYOPATHY, HYPERTROPHIC; CELLS, CULTURED; CYTOKINES; FEMALE; FIBROBLASTS; FIBROSIS; GALECTIN 3; HUMANS; HYPERTENSION; HYPERTROPHY; KIDNEY; LIPOCALINS; MALE; MICE; MYOCARDIUM; MYOCYTES, SMOOTH MUSCLE; NEPHRECTOMY; OBESITY, ABDOMINAL; ONCOGENE PROTEINS; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROTO-ONCOGENE PROTEINS; RATS; RECOMBINANT PROTEINS;

EID: 84940025127     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05431     Document Type: Article

References (34)

1. Messaoudi S, Azibani F, Delcayre C, Jaisser F., Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol 2012 350 266 272. doi: 10.1016/j.mce.2011.06.038
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 341 709 717. doi: 10.1056/NEJM199909023411001
3. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011 364 11 21. doi: 10.1056/NEJMoa1009492
4. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 348 1309 1321. doi: 10.1056/NEJMoa030207
5. Latouche C, El Moghrabi S, Messaoudi S, Nguyen Dinh Cat A, Hernandez-Diaz I, Alvarez de la Rosa D, Perret C, López Andrés N, Rossignol P, Zannad F, Farman N, Jaisser F., Neutrophil gelatinase-Associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. Hypertension 2012 59 966 972. doi: 10.1161/HYPERTENSIONAHA.111.187872
6. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, Barasch J., Dual action of neutrophil gelatinase-Associated lipocalin. J Am Soc Nephrol 2007 18 407 413. doi: 10.1681/ASN.2006080882
7. Savoia C, Touyz RM, Amiri F, Schiffrin EL., Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 2008 51 432 439. doi: 10.1161/HYPERTENSIONAHA.107.103267
8. Chakraborty S, Kaur S, Guha S, Batra SK., The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta 2012 1826 129 169. doi: 10.1016/j.bbcan.2012.03.008
9. Yan L, Borregaard N, Kjeldsen L, Moses MA., The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-Associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001 276 37258 37265. doi: 10.1074/jbc.M106089200
10. Triebel S, Bläser J, Reinke H, Tschesche H., A 25 kDa alpha 2-microglobulin-related protein is a component of the 125 kDa form of human gelatinase. FEBS Lett 1992 314 386 388
11. Auguet T, Quintero Y, Terra X, Martínez S, Lucas A, Pellitero S, Aguilar C, Hernández M, del Castillo D, Richart C., Upregulation of lipocalin 2 in adipose tissues of severely obese women: positive relationship with proinflammatory cytokines. Obesity (Silver Spring) 2011 19 2295 2300. doi: 10.1038/oby.2011.61
12. Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, Chow WS, Wat NM, Xu JY, Hoo RL, Xu A., Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007 53 34 41. doi: 10.1373/clinchem.2006.075614
13. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Silva C, Rotellar F, Gil MJ, Cienfuegos JA, Salvador J, Frühbeck G., Increased adipose tissue expression of lipocalin-2 in obesity is related to inflammation and matrix metalloproteinase-2 and metalloproteinase-9 activities in humans. J Mol Med (Berl) 2009 87 803 813. doi: 10.1007/s00109-009-0486-8
14. Krug AW, Ehrhart-Bornstein M., Adrenocortical dysfunction in obesity and the metabolic syndrome. Horm Metab Res 2008 40 515 517. doi: 10.1055/s-2008-1073154
15. Schinner S, Willenberg HS, Krause D, Schott M, Lamounier-Zepter V, Krug AW, Ehrhart-Bornstein M, Bornstein SR, Scherbaum WA., Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int J Obes (Lond) 2007 31 864 870. doi: 10.1038/sj.ijo.0803508
16. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM., Weight loss and the renin-Angiotensin-Aldosterone system. Hypertension 2005 45 356 362. doi: 10.1161/01.HYP.0000154361.47683.d3
17. Eschalier R, Rossignol P, Kearney-Schwartz A, Adamopoulos C, Karatzidou K, Fay R, Mandry D, Marie PY, Zannad F., Features of cardiac remodeling, associated with blood pressure and fibrosis biomarkers, are frequent in subjects with abdominal obesity. Hypertension 2014 63 740 746. doi: 10.1161/HYPERTENSIONAHA.113.02419
18. Iraqi W, Rossignol P, Angioi M, Fay R, Nuee J, Ketelslegers JM, Vincent J, Pitt B, Zannad F., Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: Insights from the eplerenone post-Acute myocardial infarction heart failure efficacy and survival study (Ephesus) study. Circulation 2009 119 2471 2479
19. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HE, Cheung CC, Mak TW., Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2006 103 1834 1839. doi: 10.1073/pnas.0510847103
20. Galmiche G, Pizard A, Gueret A, El Moghrabi S, Ouvrard-Pascaud A, Berger S, Challande P, Jaffe IZ, Labat C, Lacolley P, Jaisser F., Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension 2014 63 520 526. doi: 10.1161/HYPERTENSIONAHA.113.01967
21. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, Lacolley P, Henrion D, Jaisser F., The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J 2010 24 2454 2463. doi: 10.1096/fj.09-147926
22. Griol-Charhbili V, Fassot C, Messaoudi S, Perret C, Agrapart V, Jaisser F., Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension 2011 57 238 244. doi: 10.1161/HYPERTENSIONAHA.110.153619
23. Liu JT, Song E, Xu A, Berger T, Mak TW, Tse HF, Law IK, Huang B, Liang Y, Vanhoutte PM, Wang Y., Lipocalin-2 deficiency prevents endothelial dysfunction associated with dietary obesity: role of cytochrome P450 2C inhibition. Br J Pharmacol 2012 165 520 531. doi: 10.1111/j.1476-5381.2011.01587.x
24. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, Poirier F, Lacolley P, Zannad F, Rossignol P, López-Andrés N., Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013 33 67 75. doi: 10.1161/ATVBAHA.112.300569
25. López-Andrés N, Martin-Fernandez B, Rossignol P, Zannad F, Lahera V, Fortuno MA, Cachofeiro V, Díez J., A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. Am J Physiol Heart Circ Physiol 2011 301 H2372 H2382. doi: 10.1152/ajpheart.00283.2011
26. Yndestad A, Landrø L, Ueland T, Dahl CP, Flo TH, Vinge LE, Espevik T, Frøland SS, Husberg C, Christensen G, Dickstein K, Kjekshus J, Øie E, Gullestad L, Aukrust P., Increased systemic and myocardial expression of neutrophil gelatinase-Associated lipocalin in clinical and experimental heart failure. Eur Heart J 2009 30 1229 1236. doi: 10.1093/eurheartj/ehp088
27. Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS, Oh DJ, Park CG., Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol 2008 158 203 207. doi: 10.1530/EJE-07-0633
28. Xiao Y, Xu A, Hui X, Zhou P, Li X, Zhong H, Tang W, Huang G, Zhou Z., Circulating lipocalin-2 and retinol-binding protein 4 are associated with intima-media thickness and subclinical atherosclerosis in patients with type 2 diabetes. PLoS One 2013 8 e66607. doi: 10.1371/journal.pone.0066607
29. Cheng JM, Akkerhuis KM, Meilhac O, Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography. Arterioscler Thromb Vasc Biol 2014 34 1078 1084. doi: 10.1161/ATVBAHA.114.303486
30. Wu G, Li H, Fang Q, Jiang S, Zhang L, Zhang J, Hou X, Lu J, Bao Y, Xu A, Jia W., Elevated circulating lipocalin-2 levels independently predict incident cardiovascular events in men in a population-based cohort. Arterioscler Thromb Vasc Biol 2014 34 2457 2464. doi: 10.1161/ATVBAHA.114.303718
31. Messaoudi S, Gravez B, Tarjus A, Pelloux V, Ouvrard-Pascaud A, Delcayre C, Samuel J, Launay JM, Sierra-Ramos C, Alvarez de la Rosa D, Clément K, Farman N, Jaisser F., Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo. Hypertension 2013 61 361 367. doi: 10.1161/HYPERTENSIONAHA.112.198986
32. Newfell BG, Iyer LK, Mohammad NN, McGraw AP, Ehsan A, Rosano G, Huang PL, Mendelsohn ME, Jaffe IZ., Aldosterone regulates vascular gene transcription via oxidative stress-dependent and-independent pathways. Arterioscler Thromb Vasc Biol 2011 31 1871 1880. doi: 10.1161/ATVBAHA.111.229070
33. Ong KL, Tso AW, Cherny SS, Sham PC, Lam TH, Lam KS, Cheung BM, Investigators of the Hong Kong Cardiovascular Risk Factor Prevalence Study Role of genetic variants in the gene encoding lipocalin-2 in the development of elevated blood pressure. Clin Exp Hypertens 2011 33 484 491. doi: 10.3109/10641963.2010.549276
34. Park CG, Choi KM., Lipocalin-2, A-FABP and inflammatory markers in relation to flow-mediated vasodilatation in patients with essential hypertension. Clin Exp Hypertens 2014 36 478 483. doi: 10.3109/10641963.2013.863320.